Dorsomorphin, DM
SKU
D-1310
- CAS:866405-64-3
- Formula:C24H25N5O
- MW:399.5 Da
- Appearance:Yellow Solid
- Purity:≥98%
SDS
CofA
Cell-permeable. A potent, selective, reversible and ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) (Ki=109 nM in the presence of ATP and no AMP). Displays no significant inhibition of JAK3, PKA, PKCθ, SYK and ZAPK. Suppresses food intake in mice and inhibits the effects of AICAR and metformin.Also inhibits bone morphogenic protein (BMP) type I receptors (ALK2, ALK3 and ALK6). Promotes cardiomyogenesis in mouse embryonic stem cells. In addition, recently Dorsomorphin has shown to induce protective autophagy in cancer cells through AMPK inhibition-independent pathway.
More Information
Alternate Name/Synonyms
BML-275; Compound C; AMPK INHIBITOR
SKU
D-1310
CAS #
866405-64-3
Chemical Name
6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine
Chemical Formula
C24H25N5O
Molecular Weight
399.5 Da
Appearance
Yellow Solid
Purity
≥98%
Solubility
May be dissolved in DMSO (4 mg/mL, warm)
Melting Point
244.93 °C
Preparation
N/A
Storage Temp
-20°C, desiccated, for up to 3 months
THERAPEUTIC AREA
Neurological Disorders
USE
BML-275 is a cell-permeable pyrazolopyrimidine compound shown to be an AMP-activated protein kinase (AMPK) and Fatty Acid Synthase inhibitor. Phosphorylation of AMPK occurs in vivo when energy sources are low and in-turn suppresses expression of SREBP-1. SREBP-1 is a key lipogenic transcription factor, and its suppression allows glucose production by hepatocytes. In mouse studies it has been reported that BML-275 rapidly reduces the level of the phosphorylated AMPK α subunit in the hypothalamus, in an ATP-competitive manner, therefore altering energy perception and affecting the physiological energy sensor of the body. Over-activation of AMPK has also been found to be deleterious in ischemic stroke conditions and inhibition of AMPK by BML-275 may provide a small level of neuroprotection. Additional research on zebrafish has shown that BML-275 also inhibits bone morphogenetic protein signals required for iron metabolism and embryogenesis. BML-275 is an inhibitor of ACTR-I, BMPR-IA and BMPR-IB.
Merck Index
N/A
MDL NUMBER
MFCD08705402
CHEMACX
X1561649-0
INCHI
InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2
SMILES
C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3
Handling
Avoid contact with skin, eyes or clothing. Use personal protective equipment as required. Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product.
Certificate of Analysis 1
Certificate of Analysis 2
Certificate of Analysis 3
| GHS PICTOGRAMS |
|
|---|---|
| Handling | Avoid contact with skin, eyes or clothing. Use personal protective equipment as required. Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product. |
Related Products
